Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Amicus Therapeutics (FOLD) PT Lowered to $14 at BofA Securities
February 19, 2025 1:48 PM ESTBofA Securities analyst Tazeen Ahmad lowered the price target on Amicus Therapeutics (NASDAQ: FOLD) to $14.00 (from $15.00) while maintaining a Buy rating.
The analyst comments "Amicus Therapeutics (FOLD, Buy, $14 PO) announced FY24 total revenue of $528.3mn (33% y/y), Galafold of $458.2mn (y/y... More
